Received a live vaccine within 30 days of the first dose of study medication
Administration of a live vaccine within 30 days prior to first dose of study drug
Received a live vaccine within 30 days prior to first dose of study drug
Has received a live vaccine within 30 days prior to the first dose of study therapy
Has received a live-virus vaccine within 30 days prior to first dose of study medication.
Has received a live vaccine within 30 days prior to the first dose of study therapy
Have received a live vaccine within 30 days before the first dose of study treatment.
Has received a live vaccine within 30 days prior to first dose of study drug.
Received a vaccine within 7 days of first dose
Received a live vaccine within 30 days of the first dose of treatment.
Has received a live attenuated vaccine within 28 days before the first dose of study drug
Has received a live vaccine within 30 days prior to the first dose of study drug
Has received a live vaccine within 30 days prior to the first dose of study treatment.
Patients who have received live, attenuated vaccine within 28 days prior to the first dose of PD-1 inhibitor.
Has received a live vaccine within 30 days prior to the first dose of study drug
Has received a live vaccine within 30 days prior to first dose
Patients who have received a live vaccine within 30 days prior to the first dose of pembrolizumab
Has received a live attenuated vaccine within 28 days before the first dose of study drug
Subjects must not have received a live vaccine within 30 days prior to the first dose of study medication
Have received a live vaccine within 30 days before the first dose of study treatment.
Has received a live vaccine within 30 days prior to the first dose of study drug
Received a live vaccine within 30 days prior to first dose of study drug
Patient has received a live vaccine within 4 weeks prior to the first dose of treatment
Have received any live vaccine within 14 days prior to first study drug administration.
Received a live attenuated vaccine within 28 days of first study dose, unable to take oral medications
Has received a live vaccine within 30 days prior to the first dose of study treatment
Received a live vaccine within 30 days prior to the first dose of study treatment.
Patient has received a live vaccine within 30 days prior to first dose
Received a live vaccine within 1 week prior to the first dose of study treatment
Has received a live vaccine within 30 days of the first dose of study therapy
Has received a live vaccine within 30 days prior to first dose of study drug.
Received a live vaccine within 30 days prior to the first dose of study medication
Live vaccine use within 30 days of first dose of study medication.
Has taken any prohibited medications that are listed in the protocol within 14 days of the first dose of study treatment. Subject has received or will receive a live vaccine within 30 days before the first administration of study treatment
Has received a live vaccine within 30 days prior to first dose.
Received or will receive a live vaccine within 30 days prior to first dose of study drug
Received a live vaccine within 30 days prior to first dose of study drug
Received a live vaccine within 30 days of the first dose of study medication
Treatment with live vaccine within 30 days prior to the first dose of study medication are not eligible
Has received a live vaccine within 30 days prior to the first dose of study drug
Has received a live vaccine within 30 days prior to the first dose of study drug
Has received a live vaccine within 30 days prior to the first dose of study treatment
Has received a live vaccine within 30 days prior to the first dose of study treatment
Has received a live vaccine within 30 days of the first dose of study treatment.
Has received a live vaccine within 30 days prior to first dose of study therapy
Have received a live vaccine within 30 days before the first dose of study treatment
Received live, attenuated vaccine within 28 days prior to the first dose of mogamulizumab;
Has received a live vaccine within 30 days prior to first dose
Has received a live vaccine within 30 days prior to the first dose of study therapy
Has received a live vaccine within 30 days prior to the first dose of study treatment
Has received a live vaccine within 30 days prior to the first dose of study treatment.
Has received a live-virus vaccine within 30 days prior to the first dose of study treatment
Received a live viral vaccine within 6 months prior to the first dose of study drug.
Has received a live vaccine within 30 days prior to first dose of study drug.
Received a live vaccine =< 30 days prior to registration
Vaccinations with a live vaccine within 28 days prior to start of treatment or need for live vaccine at any time during study treatment.
Has received a live vaccine ? 30 days prior to study registration
Has received a live vaccine within 30 days prior to the initiation of lymphodepletion.
Has received a live vaccine within 28 days prior to registration
Received live vaccine within 28 days prior to enrollment
Live vaccine ? 4 weeks prior to enrollment
Received any live vaccine within the last 30 days
Patients who have received a live vaccine within 30 days prior initiation of the systemic regimen
Received a live vaccine within 4 weeks prior to the start of study drug
Patients who have received a live vaccine within 30 days prior initiation of the systemic regimen
Has received a live vaccine within 30 days of first study procedure (apheresis)
Received a live vaccine within 30 days prior to start of study treatment
Received a live vaccine =< 30 days prior to registration
Received live vaccine within 28 days prior to enrollment
Received a live vaccine =< 30 days prior to registration
Has received a live vaccine within 30 days prior to registration
Received a live vaccine within 30 days of first protocol treatment
Patients who have received a live attenuated vaccine =< 30 days prior to registration are not eligible
Received live vaccine =< 30 days prior to registration
History of receiving a live vaccine 30 days prior to study treatment.
Received live vaccine within 28 days prior to enrollment
Live vaccine within 30 days prior to treatment initiation.
Patients who have received a live vaccine within 30 days prior to the radiation therapy
Has received a live vaccine within 30 days prior to the first protocol treatment
Received any live vaccine =< 30 days prior to registration
Has received a live vaccine within 30 days prior to transplant admission
Has received a live virus vaccine within 30 days of allocation.
Has received a live virus vaccine within 30 days of randomization.
Received live vaccine within 28 days prior to enrollment
Subject has received a live virus vaccine within the previous 8 weeks.
Patients planning for a live vaccine
Live vaccine ? 6 weeks prior to start of conditioning regimen
Has received a live vaccine within 30 days prior to trial registration.
Has received a live vaccine within 30 days prior to the radiation therapy
Live vaccine within 30 days prior to registration.
Patient who have received a live vaccine within 30 days prior to cycle 1 day 1
Participant has received a live vaccine within 2 weeks (less than 14 days) prior to C1D1
Subject has received a live vaccine within 4 weeks prior to C1D1
Any patient receiving a live vaccine must allow a 4-week interval before starting treatment on this study
Participant has received a live vaccine within 4 weeks prior to screening
Received live vaccine within 28 days prior to enrollment
Received a live vaccine within 30 days prior to day 1
Live vaccine ? 4 weeks prior to enrollment
Received live vaccine within 28 days prior to enrollment.
Has received a live vaccine within 30 days prior to randomization.
Received live vaccine within 28 days prior to enrollment.
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
SAFETY RUN-IN: Has received a live vaccine within 30 days prior to the first dose of trial treatment
RANDOMIZED PHASE II CLINICAL TRIAL: Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial drug.
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Live vaccine within 4 weeks of the first dose of pembrolizumab and while on trial is prohibited
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Have received a live vaccine within 30 days prior to the first dose of trial treatment.
Received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Subject has received a live vaccine within 30 days prior to the first dose of trial treatment
Have received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment.
Is known to have received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
The participant has received a live vaccine within 30 days prior to the first dose of trial treatment.
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Patients who have received a live vaccine within 30 days prior to the first dose of trial treatment.
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Has received a live vaccine within 30 days prior to the first dose of trial treatment
Have received a live-virus vaccine within 30 days prior to planned treatment start.
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 28 days of planned start of study therapy
Has received a live vaccine within 28 days of planned start of study therapy
Patients who have received a live vaccine within 30 days of the planned start of study therapy
Must not have received a live vaccine within 30 days of planned start of the study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Received live vaccine within 30 days of planned start of study medication
Received a live vaccine within 30 days of planned start of study medication
Has received a live vaccine within 28 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of trial therapy.
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Received a live virus vaccine within 30 days of planned start of therapy
Has received a live vaccine within 30 days of planned start of study therapy.
Received a live virus vaccine within 30 days of planned start of study treatment
Has received a live vaccine within 30 days of planned start of study therapy.
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 30 days of planned start of study therapy
Received a live vaccine =< 30 days of planned start of study therapy
Received a live vaccine within 30 days of planned start of study medication
Has received a live vaccine within 30 days of planned start of study drug (Cycle 1, Day 1).
Has received a live vaccine within 30 days of planned start of study therapy.
Live vaccine within 30 days of planned start of study drug
Received a live virus vaccine within 30 days of planned study start
Has received a live virus vaccine within 30 days of planned start of trial treatment
Has received a live vaccine within 30 days of planned start of study drug (Cycle 1, Day 1)
Has received a live vaccine within 30 days of the planned first dose of the study
Receipt of a live vaccine within 30 days of planned start of study therapy.
Received a live vaccine within 30 days of planned start of study medication
Live vaccine within 30 days of planned start of study therapy
Received a live vaccine within 30 days of planned start of study medication
Received a live virus vaccine within 30 days of planned start of study treatment
Received a live virus vaccine within 30 days of planned start of trial treatment
Received live vaccine within 30 days of planned start of study therapy
Live vaccine within 30 days of planned start of study therapy
Has received live vaccine within 30 days of the planned start of study therapy
Received a live vaccine within 30 days of planned start of study treatment
Has received a live vaccine within 30 days of planned start of study therapy.
Has received a live vaccine within 30 days prior to the planned first dose of study therapy.
Patient who received a live vaccine within 30 days of planned start of study therapy
Patient who received a live vaccine within 30 days of planned start of study therapy
Has received a live vaccine within 28 days of planned start of study therapy
Received a live vaccine within 30 days of planned PD-1 start date.
Receipt of a live vaccine within 30 days of planned start of study drug.
Receipt of a live vaccine within 30 days of planned start of study therapy
Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
Received a live-virus vaccination within 30 days of planned treatment start.
Has received a live vaccine within 30 days of the planned start of study therapy. Seasonal flu vaccines that do not contain live virus are permitted.
Live-virus vaccination -4 weeks NOTE: Seasonal flu vaccines that do not contain live virus are not an exclusion.
Received live-virus vaccination within 30 days (seasonal flu vaccine allowed if non-live virus)
Has received a live-virus vaccine within 30 days of planned start of study drug. Seasonal flu vaccines that do not contain live virus are permitted.
Has received a live-virus vaccination within 28 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
Live-virus vaccination within 30 days of the first dose of mRNA-4157 or pembrolizumab. Seasonal flu vaccines that do not contain live virus are permitted
Has received a live-virus vaccination within 30 days of planned treatment start.
Has received a live-virus vaccination within 30 days of planned treatment start
Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted
Has received a live-virus vaccination within 30 days of planned start of study therapy. Seasonal flu vaccines that do not contain live virus are permitted.
Has received a live-virus vaccination within 30 days of planned treatment start. Note: Seasonal flu vaccines that do not contain live virus are permitted.
Has received or will receive a live vaccine within 30 days prior to the first administration of study medication; seasonal flu vaccines that do not contain live virus are permitted
Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
Has received a live-virus vaccination within 30 days of planned treatment start.
Previous treatment with live vaccine within 30 days of planned start of study drugs (seasonal flu vaccines that do not contain a live virus are permitted).
Has received a live-virus vaccination within 30 days prior to start of study drug treatment. a. Seasonal flu and other inactivated vaccines that do not contain live virus are permitted.
Receipt of live vaccination within 28 days before randomization; seasonal flu vaccines that do not contain live virus are permitted
Has received a live-virus vaccination within 30 days of planned treatment start. Note: Seasonal flu vaccines that do not contain live virus are permitted.
Received a live-virus vaccination within 30 days of planned start of study medication.
Has received a live vaccine within 30 days of the planned start of study therapy. Seasonal flu vaccines that do not contain live virus are permitted.
Have received a live vaccine within 30 days prior to enrollment. Seasonal flu vaccines that do not contain live virus are permitted.
Has received a live-virus vaccination within 30 days of planned treatment start
Participant has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.
Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted
Has received a live-virus vaccination within 30 days of planned start of study therapy. Seasonal flu vaccines that do not contain live virus are permitted.
Patients must not have received any live vaccine within 30 days prior to registration; seasonal flu vaccines that do not contain live virus are permitted